Thermo Fisher paid $9 billion for Clario and got $30 million back in Q1. That’s a partial-quarter yield: the deal closed late March, contributing $0.01 to adjusted EPS on top of the company’s 6% earnings beat.
Q1 total revenue hit $11.01 billion, up from $10.36 billion a year ago. Adjusted EPS came in at $5.44, beating internal targets. The laboratory products and biopharma services segment drove most of the gain: $6.04 billion, up 7% from $5.64 billion in Q1 2025. Analytical instruments and specialty diagnostics were the weak spots.
Clario is a clinical trial data company. What does the $9B check actually buy? Clario’s data infrastructure for trial operations.
CEO Marc Casper told investors AI “is going to improve the returns on investment for the drug development industry,” predicting more pipeline products and stronger biotech funding. He flagged “some modest level of inflationary pressure” from Middle East conflict, but said customers “remain focused on advancing their priorities.”
On 2026 guidance, Thermo Fisher raised its revenue target to $47.3 billion to $48.1 billion, up from $46.3 billion to $47.2 billion. Adjusted EPS guidance moved to $24.64 to $25.12 from $24.22 to $24.80.
The full Clario read comes in Q2.
Diana Kowalski